help button home button Am J Pathol R & D Systems
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zadeh, G.
Right arrow Articles by Guha, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zadeh, G.
Right arrow Articles by Guha, A.
(American Journal of Pathology. 2004;164:467-476.)
© 2004 American Society for Investigative Pathology

Targeting the Tie2/Tek Receptor in Astrocytomas

Gelareh Zadeh*, Baoping Qian*, Ali Okhowat*, Nesrin Sabha*, Christopher D. Kontos{dagger} and Abhijit Guha*{ddagger}

From the Arthur and Sonia Labatt Brain Tumor Center,* Hospital for Sick Children, and the Division of Neurosurgery,{ddagger} Western Hospital, University of Toronto, Toronto, Canada; and the Department of Medicine,{dagger} Division of Cardiology, Duke University Medical Center, Durham, North Carolina

Tie2 is an endothelial cell-specific receptor tyrosine kinase, whose activation is positively and negatively modulated by angiopoietin-1 and angiopoietin-2, respectively. Angiopoietin-mediated modulation of Tie2 activation contributes to normal vessel development and stability, however, its role in tumor angiogenesis is not well known. We investigated the role of Tie2 activation in malignant astrocytomas, a common and highly vascularized primary human brain tumor. We found that Tie2 expression and activation increases with increasing malignancy grade of astrocytomas. Inhibition of Tie2, using a kinase-deficient Tie2 construct, decreases growth of malignant human astrocytoma subcutaneous and intracranial xenografts. Tie2 inactivation disrupted the tumor vascularity, with a decrease in microvascular density, increased presence of abnormally dilated vessels, and loss of interaction between endothelial cells and surrounding smooth muscle cells, all collectively resulting in increased tumor cell apoptosis. Overall, these findings strongly suggest that Tie2 activation contributes significantly to astrocytoma tumor angiogenesis and growth. We postulate that targeting Tie2 activation, either independently or in conjunction with other anti-angiogenic therapies, such as against vascular endothelial growth factor, is of potential clinical interest.




This article has been cited by other articles:


Home page
 EndocrinologyHome page
A. Johansson, S. H. Rudolfsson, P. Wikstrom, and A. Bergh
Altered Levels of Angiopoietin 1 and Tie 2 Are Associated with Androgen-Regulated Vascular Regression and Growth in the Ventral Prostate in Adult Mice and Rats
Endocrinology, August 1, 2005; 146(8): 3463 - 3470.
[Abstract] [Full Text] [PDF]

Home page
 Neuro OncolHome page
B. Kaur, F. W. Khwaja, E. A. Severson, S. L. Matheny, D. J. Brat, and E. G. Van Meir
Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis
Neuro-oncol, April 1, 2005; 7(2): 134 - 153.
[Abstract] [PDF]

Home page
 Am. J. Pathol.Home page
M. R. Machein, A. Knedla, R. Knoth, S. Wagner, E. Neuschl, and K. H. Plate
Angiopoietin-1 Promotes Tumor Angiogenesis in a Rat Glioma Model
Am. J. Pathol., November 1, 2004; 165(5): 1557 - 1570.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by the American Society for Investigative Pathology.